For the TP53 wild type cell lines, overall solid response to combination treatments was detected in the MDS-AML cell line MOLM-13, which presented moderate synergy to PTC596 in combination with S63845, trametinib, or PKC-412, as well as mild synergy to PTC596 in combination with HDM201 and APR-246. This evidence concerns the gene PRRT2 and acute myeloid leukemia.